H19 and pulmonary arterial hypertension: Nevertheless, as this result was inferred from an in vitro model, it needs to be verified in vivo by assessing the differential expression of H19 in different cardiac cell types of the RV after PAH injury, ideally including loss-of-function experiments with gapmeR treatment.